Almac Discovery and RCSI enter research collaboration

By Melissa Fassbender

- Last updated on GMT

Graham Cotton, Senior R&D Group Leader, Almac Discovery; Tracy Robson; and Professor Tim Harrison, VP Discovery Chemistry, Almac Discovery.
Graham Cotton, Senior R&D Group Leader, Almac Discovery; Tracy Robson; and Professor Tim Harrison, VP Discovery Chemistry, Almac Discovery.

Related tags Oncology

Almac Discovery and the Royal College of Surgeons in Ireland (RCSI) and have announced a research collaboration aimed at understanding how to target therapy-resistant cancer tumors.

The collaboration will explore the potential of ALM201, which is currently undergoing a Phase I dose escalation trial for patients with solid tumors. The trial is expected to be expanded in a biomarker selected patient population within ovarian cancer.

ALM201 is peptide fragment of FKBPL that Almac Discovery has in clinical development​,” Martin Wiles, Vice President Business Development and Licensing at Almac Discovery told us.

The current plan is to investigate the anti-angiogenic properties in ovarian cancer patients; however this work is looking at a different angle on ALM201’s mode of action - that of inhibition of cancer stem cell/tumor initiation​,” he explained.

Tracy Robson, the initial researcher looking at FKBPL and its peptides who identified the stem cell aspect to ALM201’s mode of action, commented that the funding provided by Almac enables the researchers to better understand the mechanism behind ALM201’s anti-cancer stem cell activity.

We hope to obtain a more refined idea of the mode of action of ALM201 and to potentially be able to better select patients who will benefit from treatment with ALM201,” ​added Wiles.

Moving forward he explained, "The work will involve investigating if ALM201 has the means to reduce the initiation of tumors initially in the ovarian cancer setting​."

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars